The Calmer Co (ASX: CCO) has secured significant regulatory clarity from the US FDA, which confirmed traditionally prepared kava beverages as food products, de-risking its US expansion and dual-category strategy.
FDA Confirms Kava as Food
The US FDA has ruled that traditionally prepared kava beverages are classified as food under US federal law. This ruling provides regulatory certainty and clarifies the pathway for kava products in the US market.
The Calmer Co's dual Food + Supplement portfolio strategy will leverage this. Beverages are now classified as food, while tinctures, capsules and flavoured Taki Mai shots continue as dietary supplements.
US eCommerce Momentum Accelerates
The Calmer Co's Fiji Kava and Taki Mai brands are experiencing strong year-over-year growth on Amazon USA. The Fiji Kava 150g Instant Kava holds the #1 branded instant kava position on Amazon USA.
Significant increases in online visibility and market share are reported for both brands. Fiji Kava has seen a +565% increase in organic search visibility and a +45% share of sales. Taki Mai reported a +3111% increase in organic search visibility and an impressive +870% share of sales.
FDA-Audited Facility Supports Expansion
The Calmer Co's Fiji facility is FDA-registered and FDA-audited. It meets high cGMP standards for dietary supplements, enhancing compliance and supporting cross-category expansion.
With more than 21 million Americans consuming kava, this regulatory certainty underpins broad distribution opportunities across retail, eCommerce, and B2B channels in the US.
Investor Implications
The FDA's classification of kava beverages as food significantly reduces regulatory risk for The Calmer Co's US market expansion. Coupled with strong e-commerce growth and an FDA-audited facility, this positions the company to accelerate its dual-category strategy and capture a larger share of the growing US kava market. Investors will watch for continued translation of online momentum into broader retail channels.
